valor de las acciones
Competidores
| Simbolo bursátil | Precio | Pronóstico 1A | Pronóstico 2A | Cap. Mercado | Div Yld | Tasa de crecimiento |
|---|---|---|---|---|---|---|
|
CPSE:NOVO B
Novo Nordisk A/S
|
850.60 | 5.1% | 26.89% | 3,778,836.67 | 1.11% | 18.5% |
|
NYSE:PFE
Pfizer
|
27.81 | 11.67% | 42.8% | 157,475.27 | 6.04% | -9.31% |
|
ENXTPA:SAN
Sanofi
|
91.30 | 16.54% | 35.07% | 114,001.35 | 4.12% | 8.19% |
|
ASX:CSL
CSL
|
275.80 | 24.38% | 45.56% | 133,281.1 | 1.29% | 7.18% |
|
TSE:4568
Daiichi Sankyo Company
|
5502.00 | 0% | 0% | 10,550,099.8 | 1.09% | 0% |
|
NasdaqGS:MRNA
Moderna
|
125.00 | -,111.39% | -,107.86% | 47,904.97 | 0% | 0% |
|
TSE:4502
Takeda Pharmaceutical Company
|
4125.00 | 0% | 0% | 6,471,852.14 | 4.56% | 0% |
|
NasdaqGS:BIIB
Biogen
|
217.51 | -10.14% | 5.81% | 31,668.78 | 0% | -10.89% |
|
XTRA:BAYN
Bayer
|
28.02 | 70.88% | 87.56% | 27,527.52 | 0.39% | 1.47% |
|
NasdaqGS:ALNY
Alnylam Pharmaceuticals Inc
|
152.33 | 0% | 0% | 19,268.49 | 0% | 0% |
|
NasdaqGS:SRPT
Sarepta Therapeutics
|
133.66 | 0% | 0% | 12,634.05 | 0% | 0% |
|
OM:SOBI
Swedish Orphan Biovitrum AB (publ)
|
280.00 | -20.47% | 10.7% | 96,998.36 | 0% | -1.05% |
|
NasdaqGS:IONS
Ionis Pharmaceuticals
|
41.97 | -,153.3% | -,146.3% | 6,121.15 | 0% | 0% |
|
BME:GRF
Grifols
|
8.89 | 273.99% | 387.61% | 5,315.22 | 0% | -19.25% |
|
NasdaqGS:DYN
Dyne Therapeutics
|
26.08 | 0% | 0% | 2,240.56 | 0% | 0% |
|
NasdaqGS:DCPH
Deciphera Pharmaceuticals
|
25.38 | 0% | 0% | 2,086.9 | 0% | 0% |
|
NasdaqGM:NTLA
Intellia Therapeutics
|
23.60 | 0% | 0% | 2,063.79 | 0% | 0% |
|
TSE:4516
Nippon Shinyaku
|
4389.00 | 0% | 0% | 293,927.52 | 2.83% | 0% |
|
NasdaqGS:BCRX
BioCryst Pharmaceuticals
|
4.45 | 0% | 0% | 918.17 | 0% | 0% |
|
ENXTAM:PHARM
Pharming Group N.V.
|
0.90 | -,641.75% | 1,467.17% | 590.27 | 0% | -,100% |
